ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
ChromaDex (NASDAQ: CDXC) will participate in Renmark Financial Communications Inc.'s Virtual Non-Deal Roadshow on June 11, 2024, at 2:00pm PST. The event will feature presentations from CEO Rob Fried and CFO Brianna Gerber, who will discuss the latest investor presentation and participate in a live Q&A session. Stakeholders and investors are encouraged to register for the live event, though access may be A replay will be available on the ChromaDex Investor Relations website. For further details, visit www.chromadex.com.
- ChromaDex's participation in the Virtual Non-Deal Roadshow increases visibility and engagement with investors.
- Featuring top executives like the CEO and CFO underscores transparency and leadership involvement.
- A live Q&A session provides direct interaction with stakeholders, potentially boosting investor confidence.
- registration for the live event might restrict direct investor access.
- Reliance on online connectivity could pose technical challenges for some participants.
The presentation will feature ChromaDex’s Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber. Topics to be covered will include the latest investor presentation followed by a live Q&A. Investors interested in participating in this event will need to register using the link below. As a reminder, registration for the live event may be limited but access to the replay after the event will be on the Investor Relations section of ChromaDex’s website, investors.chromadex.com.
REGISTER HERE: https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-nasdaq-cdxc-2024-06-11-140000
Tuesday, June 11, 2024:
- To ensure smooth connectivity, please access this link using the latest version of Google Chrome.
For additional information on ChromaDex, visit www.chromadex.com.
About ChromaDex:
ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen® (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.
Niagen is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in
†Based on the top-selling dietary supplement brands by revenue per the largest
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604102357/en/
ChromaDex Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships
310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
Source: ChromaDex Corporation
FAQ
What is the date and time of ChromaDex's Virtual Non-Deal Roadshow?
Who will be presenting at ChromaDex's Virtual Non-Deal Roadshow?
How can investors register for ChromaDex's Virtual Non-Deal Roadshow?
Will there be a replay available for ChromaDex's Virtual Non-Deal Roadshow?